Viridian's Lumvoa Approved by FDA, Launched for Thyroid Eye Disease

Viridian Therapeutics said it launched its first commercial product Lumvoa over the weekend, days after the Food and Drug Administration approved the intravenous therapy for thyroid eye disease. The company began commercial shipments on Saturday, it said in a statement.

The approval marks a turning point for the company, which had no marketed products before Lumvoa. The stock has been volatile as investors weighed the FDA decision, and the launch now shifts attention to commercial execution.

Thyroid eye disease is a rare autoimmune condition that causes eye pain, double vision, and bulging. The market is currently dominated by Amgen's Tepezza, a drug that generated more than $2 billion at its peak before facing supply problems and new rivals. Lumvoa enters as a direct alternative.

The challenge is considerable. Viridian must persuade doctors to try a new therapy, win coverage from insurers, and build a sales team. The company has not disclosed pricing but said Lumvoa would be priced competitively.

Tepezza's sales have slipped from their high, leaving room for a challenger. Viridian's drug was studied in late-stage trials that met their goals on eye bulging and response rates, though no direct comparison to Tepezza was done.

Lumvoa is now available by prescription. The company expects to share an initial commercial update with second-quarter results.